BrightKaire Platform for Depression
Major Depressive Disorder (MDD)
Key Facts
About NeuroKaire
NeuroKaire is developing an AI-enabled precision medicine platform for central nervous system (CNS) disorders, integrating patient-derived neuronal models with multi-modal data analysis. The company's core technology involves reprogramming a patient's blood cells into iPSC-derived neurons, exposing them to compounds, and using computer vision and deep learning to generate a predictive score for drug efficacy and safety. This approach targets the high failure rates and trial-and-error nature of current psychiatric and neurological treatments, offering a novel solution for providers, patients, and pharmaceutical partners. Founded in 2021, the company is building a comprehensive biobank and data repository to fuel its predictive algorithms.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (MDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| AL001 | Alzamend Neuro | Preclinical |
| Deep TMS (H1 Coil) | BrainsWay | FDA Cleared |
| EXXUA™ (gepirone ER) | Aytu BioPharma | Commercial |
| ZZ6398 | Zhongze Therapeutics | Phase 1/2 |
| INV-202 (Oral & LAI) | Indivior | Preclinical |
| NeuroStar Advanced Therapy | Neuronetics | FDA Cleared |
| Gepirone ER | Fabre-Kramer Pharmaceuticals | NDA Submitted |
| Exablate Neuro | Insightec | Clinical Trial |
| Tyemvers (CKDB-501) | Healis Therapeutics | Pre-clinical |
| VENTURA-7 | New Hope Clinical Research | Phase 2/3 |
| DT-101 | Draig Therapeutics | Phase 2 |
| Major Depressive Disorder Program | Actipulse Neuroscience | Phase 3 |